NeuroMetrixNURO
NURO
About: NeuroMetrix Inc is a commercial-stage healthcare company. Its core business activities are integrated with in-house capabilities spanning product development, manufacturing, regulatory affairs and compliance, sales and marketing, and customer support. The company produces bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The product line of the company includes Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The company operates in a single segment being Medical equipment and consumables.
Employees: 26
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
27% more funds holding
Funds holding: 11 [Q2] → 14 (+3) [Q3]
20% more capital invested
Capital invested by funds: $205K [Q2] → $246K (+$40.9K) [Q3]
0.25% more ownership
Funds ownership: 2.76% [Q2] → 3.01% (+0.25%) [Q3]
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Research analyst outlook
We haven’t received any recent analyst ratings for NURO.
Financial journalist opinion
Based on 3 articles about NURO published over the past 30 days
Neutral
PRNewsWire
3 days ago
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of NeuroMetrix, Inc. - NURO
NEW YORK , Dec. 18, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating NeuroMetrix, Inc. (NASDAQ: NURO ), relating to the proposed merger with electroCore, Inc. Under the terms of the agreement, shareholders of NeuroMetrix will be entitled to receive the equivalent of the balance of NeuroMetrix's net cash at the closing of the transaction, estimated to be $9 million in the aggregate.
Neutral
Business Wire
4 days ago
NURO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NeuroMetrix, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of NeuroMetrix, Inc. (NASDAQ: NURO) to electroCore, Inc. is fair to NeuroMetrix shareholders. Halper Sadeh encourages NeuroMetrix shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether NeuroMetrix and its board of direct.
Neutral
GlobeNewsWire
4 days ago
NeuroMetrix to be Acquired by electroCore
WOBURN, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (“NeuroMetrix” or the “Company”) (Nasdaq: NURO) today announced it has entered into a definitive merger agreement whereby electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a commercial stage bioelectronic medicine and wellness company, will acquire NeuroMetrix.
Negative
Zacks Investment Research
1 month ago
NeuroMetrix Q3 Loss Narrows Y/Y, Quell Sales Drives Growth
Despite a 51% revenue dip, NURO narrowed losses in Q3 2024 by reducing operating expenses by 25%, offsetting the challenging revenue environment.
Neutral
GlobeNewsWire
4 months ago
NeuroMetrix Reiterates its Review of Strategic Alternatives
WOBURN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today for the purpose of clarity, reiterated that the Company is engaged in a review of strategic alternatives.
Neutral
Seeking Alpha
4 months ago
NeuroMetrix, Inc. (NURO) Q2 2024 Earnings Call Transcript
NeuroMetrix, Inc. (NASDAQ:NURO ) Q2 2024 Earnings Conference Call August 6, 2024 8:00 AM ET Company Participants Thomas Higgins - Senior Vice President and Chief Financial Officer Shai Gozani - Founder and Chief Executive Officer Conference Call Participants Jarrod Cohen - JM Cohen & Company Operator Good morning, and welcome to the NeuroMetrix Second Quarter 2024 Business and Financial Update. My name is Amy, and I will be your moderator on the call.
Neutral
GlobeNewsWire
4 months ago
NeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference Call
WOBURN, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2024 second quarter business and financial highlights before the opening of the market on August 6, 2024.
Neutral
GlobeNewsWire
7 months ago
NeuroMetrix Reports Q1 2024 Business Highlights
WOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2024.
Neutral
GlobeNewsWire
8 months ago
NeuroMetrix Announces Steps Taken to Enhance Shareholder Value
Joshua S. Horowitz joins Board of Directors At-the-market equity facility terminated WOBURN, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced two steps to enhance shareholder value following feedback and recommendations from one of its largest shareholders, Ephraim Fields of Echo Lake Capital.
Neutral
GlobeNewsWire
9 months ago
NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy
WOBURN, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of a large study demonstrating that DPNCheck® combined with standard EKG or DPNCheck alone accurately detects diabetic peripheral neuropathy (DPN).
Charts implemented using Lightweight Charts™